Onconetix Inc
NASDAQ:ONCO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Onconetix Inc
NASDAQ:ONCO
|
US |
|
Medx Health Corp
XTSX:MDX
|
CA |
|
Aspire Biopharma Holdings Inc
NASDAQ:ASBP
|
PR |
|
T
|
Taihan Textile Co Ltd
KRX:001070
|
KR |
|
M
|
Metallica Metals Corp
CNSX:MM
|
CA |
|
K
|
Komo Plant Based Foods Inc
OTC:KOMOF
|
CA |
|
Innovest Global Inc
OTC:IVST
|
US |
|
A
|
Air France KLM SA
F:AFR
|
FR |
Onconetix Inc
Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. The firm is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The firm has Entadfi, a Food and Drug Administration (FDA) approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer.
Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. The firm is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The firm has Entadfi, a Food and Drug Administration (FDA) approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient’s risk of having clinically significant prostate cancer.
